ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. We show 36 historical shares outstanding datapoints in our ABIO shares outstanding history coverage, used to compute ABIO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABIO market cap history over the course of time is important for investors
interested in comparing ABIO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABIO versus a peer is one thing; comparing
ABIO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABIO can fluctuate over the course of history.
With this page we aim to empower investors researching ABIO by allowing them to research the ABIO market cap history. |
Free ABIO Email Alerts:
Video: The Importance of Market Cap
